The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Annals of palliative medicine"
DOI: 10.21037/apm-21-3965
Abstract: BACKGROUND Human epidermal growth factor receptor 2 (HER2)-positive breast cancer tends to metastasize and is associated with poor prognosis. Anti-HER2 treatment combined with chemotherapy or endocrine therapy is often used for HER2-positive metastatic breast cancer… read more here.
Keywords: lapatinib resistant; pyrotinib based; breast cancer; her2 ... See more keywords
HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
Sign Up to like & getrecommendations! Published in 2018 at "BMB Reports"
DOI: 10.5483/bmbrep.2018.51.12.259
Abstract: Human epidermal growth factor receptor 2 (HER2) inhibitors, such as trastuzumab and lapatinib are used to treat HER2-positive breast and gastric cancers. However, as with other targeted therapies, intrinsic or acquired resistance to HER2 inhibitors… read more here.
Keywords: her2 positive; gastric cancer; lapatinib resistant; intrinsic acquired ... See more keywords